CSF2 and autoimmune pulmonary alveolar proteinosis: In this patient, follow-up demonstrated progressive improvement in DLCO and symptom burden, without evidence of fibrotic progression on imaging, with other reports of GM-CSF therapy, and no fibrotic progression on imaging, which further supports the long-term benefit of inhaled GM-CSF therapy in autoimmune PAP.